Serotonin Pharmacology

Correct Answer

C — Palonosetron

Rationale

Palonosetron has a half-life of approximately 40 hours, substantially longer than ondansetron, granisetron, and dolasetron, which have half-lives of only a few hours. This prolonged duration distinguishes palonosetron within the serotonin type 3 antagonist class and makes it the preferred agent when coverage extending beyond 24 hours is needed.

Correct Answer

A — Neurokinin type 1 receptor antagonist

Rationale

Aprepitant is classified as a neurokinin type 1 receptor antagonist. It blocks the substance P receptor — neurokinin type 1 — which mediates the delayed phase of chemotherapy-induced nausea and vomiting occurring more than 24 hours after chemotherapy. Serotonin type 3 antagonism describes the setron class (ondansetron, palonosetron). Dopamine D2 antagonism describes metoclopramide and domperidone. Serotonin type 4 agonism describes prucalopride and cisapride.

Correct Answer

D — Cisapride

Rationale

Cisapride was a serotonin type 4 receptor agonist used as a prokinetic agent but was withdrawn from the United States market after reports of serious cardiac arrhythmias — specifically QT interval prolongation and torsades de pointes — particularly when combined with cytochrome P450 3A4 inhibitors that raised cisapride plasma levels. Metoclopramide is a dopamine D2 antagonist and serotonin type 4 partial agonist that remains in clinical use. Palonosetron is a serotonin type 3 antagonist. Prucalopride is the selective serotonin type 4 agonist currently approved for chronic idiopathic constipation, developed as a safer replacement for cisapride.

Correct Answer

B — Somatostatin analog

Rationale

Octreotide is classified as a somatostatin analog — a long-acting synthetic version of the endogenous inhibitory peptide somatostatin. It binds somatostatin receptors on enterochromaffin-like cells and carcinoid tumor cells, suppressing the secretion of serotonin and other vasoactive mediators. Tryptophan hydroxylase inhibition describes telotristat. Neurokinin type 1 antagonism describes aprepitant. Serotonin type 3 antagonism describes the setron class.

Correct Answer

A — Tryptophan hydroxylase inhibitor

Rationale

Telotristat ethyl is classified as a tryptophan hydroxylase inhibitor. Tryptophan hydroxylase is the rate-limiting enzyme in serotonin synthesis, and inhibiting it in the gut reduces serotonin production by carcinoid tumor cells and enterochromaffin cells. Telotristat is used as an add-on therapy in carcinoid syndrome when octreotide alone does not adequately control diarrhea. Somatostatin analog describes octreotide. Serotonin type 3 antagonism describes the setron class. Monoamine oxidase A inhibitors increase serotonin levels rather than reducing them.

Correct Answer

C — Peripheral dopamine D2 antagonist that does not cross the blood-brain barrier

Rationale

Domperidone is classified as a dopamine D2 antagonist with the key distinguishing property that it does not cross the blood-brain barrier at therapeutic doses. This restricts its antiemetic and prokinetic effects to the periphery and to the chemoreceptor trigger zone, which lies outside the blood-brain barrier, while sparing the striatum and other central dopaminergic pathways. As a result, domperidone does not cause the extrapyramidal adverse effects — akathisia, tardive dyskinesia — seen with metoclopramide, which freely crosses the blood-brain barrier. Option B describes metoclopramide. Option A describes prucalopride's peripheral restriction. Option D does not describe an established drug class.

Correct Answer

D — Acute phase: serotonin acting on serotonin type 3 receptors on vagal afferents; delayed phase: substance P acting on neurokinin type 1 receptors in the brainstem

Rationale

Chemotherapy damages the gastrointestinal mucosa, triggering enterochromaffin cells to release large amounts of serotonin during the first 24 hours. This serotonin activates serotonin type 3 receptors on vagal afferent neurons, driving the acute emetic response — which is why serotonin type 3 antagonists such as ondansetron are most effective for acute chemotherapy-induced nausea and vomiting. Beyond 24 hours, the delayed phase is dominated by substance P acting on neurokinin type 1 receptors in the brainstem dorsal vagal complex, which is why aprepitant — a neurokinin type 1 antagonist — provides additional benefit for delayed emesis when added to a setron. Dopamine D2 receptor activation in the chemoreceptor trigger zone contributes to emesis from other stimuli but does not drive the biphasic chemotherapy response in the same mechanistic pattern. Histamine H1 blockade addresses motion sickness, not chemotherapy-induced nausea and vomiting.

Correct Answer

A — Intravenous administration produces higher peak plasma concentrations, increasing cardiac ion channel blockade

Rationale

Ondansetron prolongs the QT interval by blocking cardiac hERG potassium channels — a pharmacological property shared with many drugs. When ondansetron is given intravenously, it enters the systemic circulation directly and reaches higher peak plasma concentrations than the same dose taken orally, which undergoes first-pass hepatic metabolism before reaching systemic circulation. These higher peak concentrations produce greater potassium channel blockade and more pronounced QT prolongation. This is why the United States Food and Drug Administration recommends limiting single intravenous doses and avoiding the intravenous route in patients with prolonged QT interval or hypokalemia. Cardiotoxic metabolites and sinoatrial node serotonin type 3 receptor activation are not established mechanisms.

Correct Answer

C — Sustained dopamine D2 receptor blockade in the striatum leads to receptor supersensitivity and involuntary movements

Rationale

Metoclopramide crosses the blood-brain barrier and blocks dopamine D2 receptors throughout the central nervous system, including in the striatum. With prolonged blockade, striatal D2 receptors undergo compensatory supersensitivity — upregulating in number and sensitivity. When this supersensitive receptor system is intermittently exposed to normal dopamine, the exaggerated response manifests as involuntary repetitive movements of the face, tongue, and limbs — tardive dyskinesia. This condition can become irreversible, which is why metoclopramide use is limited to 12 weeks. Serotonin type 4 agonism is metoclopramide's prokinetic mechanism but does not cause tardive dyskinesia. Metoclopramide does not inhibit serotonin reuptake and does not produce acetylcholine excess.

Correct Answer

B — The liver normally inactivates serotonin from portal blood; hepatic metastases bypass this by draining serotonin directly into hepatic veins

Rationale

Serotonin released by a gut carcinoid tumor enters the portal circulation, and the liver — through monoamine oxidase A activity — efficiently inactivates it before it can reach the systemic circulation. This is why a patient with a bowel carcinoid and an intact liver does not develop carcinoid syndrome despite high local serotonin production. When carcinoid tumors metastasize to the liver, the metastatic deposits drain their serotonin directly into hepatic veins, bypassing the portal first-pass inactivation system and releasing serotonin into the systemic circulation. It is the anatomical bypass of hepatic inactivation — not simply greater tumor mass — that allows systemic serotonin exposure. Biliary serotonin excretion is not a relevant mechanism, and hepatic metastases do not selectively reduce monoamine oxidase A expression.

Correct Answer

D — Aprepitant inhibits cytochrome P450 3A4, the enzyme responsible for dexamethasone metabolism, raising dexamethasone plasma concentrations

Rationale

Dexamethasone is metabolized primarily by cytochrome P450 3A4. Aprepitant is a moderate inhibitor of cytochrome P450 3A4, and when the two drugs are co-administered, aprepitant slows dexamethasone metabolism — raising dexamethasone plasma concentrations above those achieved with dexamethasone alone. To avoid excessive glucocorticoid exposure, dexamethasone doses in the standard triple antiemetic regimen are reduced by approximately 50 percent compared to dexamethasone monotherapy doses. This is a clinically established pharmacokinetic interaction that prescribers must account for when building the antiemetic regimen. Plasma protein displacement does not produce sustained clinically meaningful drug interactions at standard doses. Aprepitant does not inhibit renal tubular transporters for dexamethasone. P-glycoprotein induction would reduce, not increase, absorption.

Correct Answer

A — These foods contain serotonin that is absorbed and metabolized to 5-hydroxyindoleacetic acid, which would falsely elevate the urine level independent of tumor activity

Rationale

Bananas, pineapples, walnuts, avocados, and several other foods contain preformed serotonin in quantities sufficient to affect urinary 5-hydroxyindoleacetic acid measurements. When ingested, this dietary serotonin is absorbed from the gastrointestinal tract, enters systemic circulation, and is degraded by monoamine oxidase A to 5-hydroxyindoleacetic acid — producing a false-positive elevation in the urine assay that could be mistaken for carcinoid tumor secretion. The dietary restriction prevents this analytical interference and ensures that elevated 5-hydroxyindoleacetic acid reflects endogenous overproduction. These foods do not inhibit monoamine oxidase A, do not convert tryptophan via an alternative pathway to 5-hydroxyindoleacetic acid, and the effect is not mediated by enterochromaffin cell stimulation.

Correct Answer

C — Domperidone does not cross the blood-brain barrier at therapeutic doses, so it cannot block striatal D2 receptors

Rationale

The extrapyramidal adverse effects of dopamine D2 antagonists — acute dystonia, akathisia, parkinsonism, and tardive dyskinesia — all result from D2 receptor blockade in the striatum, a structure within the blood-brain barrier. Metoclopramide freely crosses the blood-brain barrier, producing D2 blockade throughout the central nervous system including the striatum. Domperidone is a large polar molecule that does not cross the blood-brain barrier at therapeutic concentrations, restricting its D2 blockade to peripheral tissues and the chemoreceptor trigger zone — which lies outside the blood-brain barrier. Because domperidone never reaches the striatum in meaningful concentrations, extrapyramidal effects do not occur. Domperidone does not have serotonin type 4 agonist activity — that property belongs to metoclopramide. Rapid central metabolism and differential receptor affinity are not the established mechanism.

Correct Answer

B — Palonosetron has a half-life of approximately 40 hours, maintaining therapeutic concentrations well into the delayed phase that shorter-acting setrons do not cover

Rationale

Palonosetron's half-life of approximately 40 hours distinguishes it from ondansetron (half-life 3 to 5 hours) and granisetron (half-life 5 to 9 hours). While shorter-acting setrons are effective for the acute phase of chemotherapy-induced nausea and vomiting occurring in the first 24 hours — when serotonin released from enterochromaffin cells drives the emetic response — their plasma concentrations fall below therapeutic levels before the delayed phase begins. Palonosetron maintains adequate receptor occupancy through this transition, providing coverage when other setrons would have cleared. While palonosetron may have allosteric receptor properties, it does not block neurokinin type 1 receptors — that is aprepitant's mechanism. Palonosetron does not produce a neurokinin-active metabolite.

Correct Answer

C — Chronic serotonin type 2B receptor activation on right-sided valvular interstitial cells drives fibrotic proliferation and leaflet thickening

Rationale

Serotonin type 2B receptors are expressed on valvular interstitial cells of the right-sided cardiac valves. Chronic activation of these receptors by the elevated circulating serotonin of carcinoid syndrome stimulates mitogenic signaling in these cells, producing fibrotic thickening of tricuspid and pulmonic valve leaflets that restricts their movement and causes regurgitation and stenosis. This is the same receptor mechanism responsible for the valvular disease associated with fenfluramine and ergotamine. Serotonin type 3 receptors mediate emesis and fast synaptic transmission — they are not expressed on valve leaflets and do not mediate this fibrotic process. Direct oxidative collagen damage and platelet-mediated thrombotic plaques are not the established mechanism of carcinoid valvulopathy.

Correct Answer

D — Sustained dopamine D2 receptor blockade in the striatum produces receptor supersensitivity, which manifests as involuntary hyperkinetic movements when dopamine stimulates the upregulated receptors

Rationale

Metoclopramide crosses the blood-brain barrier and produces sustained dopamine D2 receptor blockade in the striatum. Over months of continuous blockade, striatal D2 receptors undergo compensatory upregulation — increasing in number and sensitivity. When normal dopaminergic transmission intermittently stimulates these supersensitive receptors, the exaggerated response produces the stereotyped involuntary orofacial movements of tardive dyskinesia — chewing, lip smacking, tongue protrusion, and grimacing. Tardive dyskinesia can become irreversible even after the drug is discontinued, which is the basis for the black box warning and the recommendation to limit metoclopramide use to 12 weeks. Serotonin type 4 agonism is metoclopramide's prokinetic mechanism at the gut but does not cause tardive dyskinesia. Metoclopramide does not inhibit serotonin reuptake and does not accumulate via direct neurotoxicity.

Correct Answer

A — Ondansetron plus aprepitant plus dexamethasone

Rationale

The standard antiemetic regimen for highly emetogenic chemotherapy is triple therapy: a serotonin type 3 antagonist such as ondansetron addresses the acute phase (0 to 24 hours) driven by serotonin released from enterochromaffin cells; aprepitant, a neurokinin type 1 antagonist, addresses the delayed phase (beyond 24 hours) driven by substance P; and dexamethasone provides complementary antiemetic benefit through mechanisms that potentiate both agents. This combination covers both mechanistically distinct phases and is the current standard of care for cisplatin and other highly emetogenic regimens. Ondansetron plus metoclopramide does not specifically address the delayed neurokinin type 1 phase. Aprepitant alone covers the delayed phase but not the acute serotonergic phase. Metoclopramide plus dexamethasone provides only partial coverage without dedicated serotonin type 3 blockade for the acute phase.

Correct Answer

B — Octreotide — acts as a somatostatin analog to suppress tumor secretion of serotonin and other vasoactive mediators during surgical manipulation

Rationale

Carcinoid crisis is a life-threatening complication of surgical manipulation of carcinoid tumors — handling the tumor triggers a massive acute release of serotonin, histamine, and other vasoactive mediators, producing profound hypotension, bronchoconstriction, and cardiac arrhythmias. Octreotide, a long-acting somatostatin analog, is administered preoperatively and intraoperatively to suppress tumor cell secretion directly, reducing the mediator surge from surgical handling. It is the established standard of care for perioperative carcinoid crisis prevention. Ondansetron addresses nausea but does not prevent the cardiovascular and bronchospastic components of carcinoid crisis. Telotristat reduces chronic serotonin synthesis over days to weeks but does not provide acute perioperative suppression of secretion. Cyproheptadine addresses serotonin type 2 receptor effects but does not suppress the upstream secretory burst from tumor manipulation.